Skip to main content

Table 3B Immunological and clinical response in patients vaccinated with mDC

From: Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Patient ID No. of Vaccinations Antigens (Type of Lysate) Median No. of Administered Cells × 106(range) DTH Best Response after 4 or More Vaccinations Vitiligo Clinical Response Response Duration (Months) Overall Survival (Months)
     L/H KLH     
9 P.M. 7 L 11.4 (9 – 24.1) - -   PR 3 14
10 P.M. 15 L 15 (2.8 – 24) ++ ++++   MR 6 22
11 R.L. 10 H 9.5 (4 – 13.4) - ++   SD 9 14
12 G.D. 16 L/H 12.6 (2.8 – 20.8) ++ +++ + CR 8 32+
13 R.G. 4 H 9.3 (8 – 26) - +++   PD - 8
14 T.A. 13 H 9 (1.2 – 12) - ++   MR 12 28+
15 B.A. 4 H 5.9 (3.7 – 12) - -   PD - 7
16 C.P. 6 H 7.8 (1.6 – 15) - ++   PD - 20
17 O.M. 4 H 11.5 (10 – 21) - -   PD - 5
18 L.B. 4 L 12.5 (10 – 15.5) - -   PD - 3
19 M.J.L. 8 L 6 (2.2 – 10) + +++ + SD 7+ 7+
20 O.G. 5 L 10 (8.8 – 12.3) - -   PD - 3
21 M.R. 4 L 9.2 (8 – 10) + ++   SD (u.t.) 3+ 3+
No. of Patients Administration Route Site No. of Inoculations       
13 mDC 13 i.d. 10 inguinal and 3 axillary 8–10       
  1. DTH, delayed-type hypersensitivity; L, autologous lysate; H, autologous homogenate; KLH, keyhole limpet hemocyanin.
  2. PD, progressive disease; MR, mixed response; SD, stabilization; PR, partial response; CR, complete response; u.t., undergoing treatment.
  3. i.d., intradermal; s.c., subcutaneous